Concepedia

Biomarker-driven Repurposing

Biomarker-Driven Repurposing is a research strategy that identifies new therapeutic uses for existing drugs by systematically analyzing molecular, genetic, or cellular biomarkers to establish mechanistic links between drug activity and disease pathology.

15

Publications

1.2K

Citations

212

Authors

100

Institutions

Publications per year

2017–2026

13

Parents

Publications

15

Machine learning identifies candidates for drug repurposing in Alzheimer’s disease

Steve Rodriguez, Clemens B. Hug, Petar V. Todorov et al. · Nature Communications · 2021 · 297 citations · Full text

, , +17

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen et al. · Blood · 2021 · 177 citations · Full text

, , +15

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Mary W. Redman, Vassiliki A. Papadimitrakopoulou, Katherine Minichiello et al. · The Lancet Oncology · 2020 · 124 citations · Full text

, , +17

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

Samuel Y. Ng, Noriaki Yoshida, Amanda L. Christie et al. · Nature Communications · 2018 · 114 citations · Full text

, , +12

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Axel Grothey, Josep Tabernero, Dirk Arnold et al. · Annals of Oncology · 2018 · 103 citations · Full text

, , +13

1–5 of 15

Authors

212

  1. DM
    David M. Weinstock

    Dana-Farber Cancer Institute, United States

    3 publications · 354 citations

    3

    h-index

  2. AV
    Alexandria Van Scoyk

    Broad Institute, United States

    2 publications · 177 citations

    2

    h-index

  3. RK
    Raphael Koch

    Dana-Farber Cancer Institute, United States

    2 publications · 177 citations

    2

    h-index

  4. AD
    Ahmet Doǧan

    Memorial Sloan Kettering Cancer Center, United States

    2 publications · 291 citations

    2

    h-index

  5. GI
    Giorgio Inghirami

    Cornell University, United States

    2 publications · 291 citations

    2

    h-index

1–5 of 212

Institutions

100

  1. National Institutes of Health

    Bethesda, United States

    3 h-index

    3 publications

    207 citations

  2. Harvard University

    Cambridge, United States

    3 h-index

    23 publications

    4.5K citations

  3. Dana-Farber Cancer Institute

    Boston, United States

    3 h-index

    28 publications

    2.9K citations

  4. Aileron (United States)

    Cambridge, United States

    2 h-index

    6 publications

    587 citations

  5. Cancer Research And Biostatistics

    Seattle, United States

    2 h-index

    2 publications

    301 citations

  6. National Human Genome Research Institute

    Bethesda, United States

    2 h-index

    2 publications

    83 citations

  7. Broad Institute

    Cambridge, United States

    2 h-index

    14 publications

    1.5K citations

  8. Massachusetts General Hospital

    Boston, United States

    2 h-index

    7 publications

    1.7K citations

1–8 of 100

Venues

  1. Nature Communications

    3 publications · 470 citations

    3

    h-index

  2. Annals of Oncology

    2 publications · 121 citations

    2

    h-index

  3. Blood

    2 publications · 240 citations

    2

    h-index

  4. PLoS ONE

    1 publications · 14 citations

    1

    h-index

  5. British Journal of Clinical Pharmacology

    BJCP · 1 publications · 17 citations

    1

    h-index

1–5